New study aims to prevent deadly complications after liver transplant

NCT ID NCT06169592

Recruiting now Disease control Sponsor: Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. Vakhidov Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 30 adults with end-stage liver cirrhosis who receive a living-donor liver transplant. Researchers track bleeding and clotting complications to identify risk factors and improve prevention strategies. The goal is to make liver transplants safer in the early recovery period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liver transplantation (right lobe from living donor)
What this could lead to: If successful, this could help doctors better predict and prevent dangerous bleeding or clotting after a liver transplant, improving patient survival.
What could go wrong: This is a small, early-stage study with only 30 participants, so results may not apply to all patients. It focuses on identifying risks, not testing a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS LIVER TRANSPLANT; COMPLICATIONS

Contacts and locations

Locations

Republican specialized scientific and practical medical center of surgery named after academician V.Vakhidov
RECRUITING

Tashkent, 100115, Uzbekistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.